Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 9/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.39 |
| ▸ | RARB | P10826 | 3/20 | 0.39 |
| ▸ | RARG | P13631 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066856 | 0.92 | PAK4 (0.45) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL18529797 | 0.89 | PAK4 (0.42) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL18529760 | 0.84 | HTR1A (0.44) | HTR1AADRA1ADRD2NPC1L1 | |
| SCHEMBL18529796 | 0.84 | BCL9 (0.44) | PAK4NAMPTPAK1HTR1A | |
| SCHEMBL16379646 | 0.82 | PAK4 (0.55) | PAK4NAMPTPAK1BRD4NPC1L1 | |
| SCHEMBL19066902 | 0.80 | PAK4 (0.48) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL19082515 | 0.79 | PAK4 (0.47) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL18529735 | 0.77 | PAK4 (0.46) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL18329069 | 0.77 | PAK4 (0.48) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL29999875 | 0.77 | PAK4 (0.48) | PAK4NAMPTPAK1HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. | 2018-08-30 | — | — | US | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MALT1, BCL9, IKBKE | PAK4 265/4885NAMPT 2565/4885PAK1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.